Chantix (Varenicline) Dosing
The standard adult dosing for varenicline (Chantix) is 0.5 mg once daily for days 1-3, then 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 through week 12, with treatment initiated 1-2 weeks before the quit date. 1, 2
Standard Adult Dosing Schedule
The FDA-approved titration schedule is:
- Days 1-3: 0.5 mg once daily (morning)
- Days 4-7: 0.5 mg twice daily
- Day 8 through week 12: 1 mg twice daily (target dose)
Take varenicline orally after eating with a full glass of water 2. Begin dosing 1-2 weeks before the target quit date, or alternatively, start varenicline and quit smoking between days 8-35 of treatment 2.
Treatment Duration
Standard treatment is 12 weeks. For patients who successfully quit at 12 weeks, an additional 12-week course (total 24 weeks) is recommended to increase long-term abstinence 1, 2. Therapy may be extended to 6 months to 1 year to promote continued cessation, though longer periods should be avoided when possible 1.
Special Populations & Dose Adjustments
Renal Impairment
- Mild to moderate renal impairment: No adjustment needed
- Severe renal impairment (CrCl <30 mL/min): Start 0.5 mg once daily, may titrate to maximum 0.5 mg twice daily
- End-stage renal disease on hemodialysis: Maximum 0.5 mg once daily if tolerated 2
Elderly Patients
No dose adjustment based on age alone 2. However, monitor renal function as elderly patients are more likely to have decreased kidney function 2.
Hepatic Impairment
No dose adjustment necessary 2.
Adolescents Under 18
Varenicline is not FDA-approved for patients under 18 years of age 2. However, recent evidence suggests conditional use may be considered for adolescents 10-18 years with moderate to severe nicotine dependence, using weight-based dosing: 1 mg daily if >55 kg, 0.5 mg daily if ≤55 kg 3. The American Thoracic Society provides a conditional recommendation for trial use in this age group, recognizing potential benefits outweigh relatively low adverse event risk 3.
Pregnant or Breastfeeding Women
Varenicline is not specifically recommended during pregnancy or breastfeeding. The FDA label does not provide specific guidance for these populations 2. Behavioral counseling interventions are preferred for pregnant persons, as pharmacotherapy data in pregnancy remain limited 4. The evidence for NRT in pregnancy shows mixed results, though most studies trend toward benefit rather than harm 4.
Contraindications & Precautions
Absolute Contraindication
Known history of serious hypersensitivity reactions or skin reactions to varenicline 2.
Special Warnings
Neuropsychiatric Events: Monitor for agitation, depressed mood, behavioral changes, suicidal ideation, or suicidal behavior. Instruct patients to stop varenicline and contact healthcare provider immediately if these occur 1, 2. Note that the FDA removed the black box warning for neuropsychiatric events after the EAGLES trial demonstrated no significant increase in neuropsychiatric adverse events compared to nicotine patches or placebo in patients with or without psychiatric disorders 1, 5, 6.
Seizure Risk: Contraindicated in patients with brain metastases due to seizure risk 1.
Psychiatric History: While earlier concerns about psychiatric adverse events have been largely disproven 1, 7, obtain psychiatric history and suicide risk assessment before prescribing 7. Patients with schizophrenia may be less likely to receive varenicline in clinical practice despite lack of definitive contraindication 8.
Common Side Effects & Management
Nausea is the most common side effect (reported in 16.3-41.9% of patients) 9. This is dose-dependent and can be managed by:
- Taking medication with food 5, 6
- Dose titration as recommended 10
- Temporary or permanent dose reduction if intolerable 2
Other common adverse effects include insomnia, abnormal dreams, headache, and fatigue 4. Cardiovascular adverse events and major cardiovascular events show no significant increase compared to placebo 4.
Alternative Dosing Strategies
Gradual Quit Approach
For patients unable or unwilling to quit abruptly: Begin varenicline and reduce smoking by 50% within first 4 weeks, another 50% in next 4 weeks, reaching complete abstinence by week 12. Continue treatment for additional 12 weeks (total 24 weeks) 2.
Flexible Dosing
Evidence suggests patients may self-regulate between 0.5 mg/day (minimum) and 1 mg twice daily (maximum), with most taking average 1.3 mg/day and achieving >40% abstinence at 12 weeks 10. Lower doses may reduce adverse effects while maintaining efficacy 10.
Lower Dose Option
A randomized trial demonstrated that 0.5 mg twice daily for 8 weeks achieved similar 1-year abstinence rates (46.4%) compared to standard 1 mg twice daily (46.5%), with similar adherence and potentially fewer side effects 11.
Clinical Monitoring
Follow-up should occur:
- Within 2-3 weeks after starting therapy
- At 12 weeks
- At end of therapy if extended beyond 12 weeks 1
Monitor for smoking status, medication adherence, adverse effects, and neuropsychiatric symptoms 1, 2.
Treatment Failure or Relapse
If patients fail initial therapy or relapse, encourage another attempt after identifying and addressing contributing factors 2. Consider switching to combination NRT or adjusting behavioral therapy intensity 1.